Abstract

Simple SummaryParkinson’s disease (PD) is the progressive neurodegenerative disorder characterized by the degeneration of dopaminergic neurons in substantia nigra and depletion of dopamine in the striatum. Many efforts are now focused on the search for agents that can weaken PD progression, prevent further neurodegeneration, and restore the degenerated dopaminergic neurons. The present study explores the effects of lactoferrin (a multifunctional protein from the transferrin family) in the MPTP-treated mice as the model of dopaminergic neuron loss. MPTP is a neurotoxin that upon systemic administration selectively destroys dopaminergic neurons of the nigrostriatal system inducing number of the symptoms observed in idiopathic PD. Our data suggest that pretreatment with human lactoferrin significantly alleviated MPTP toxicity. This was manifested in improved motor functions and exploratory behavior, partial recovery of the number of tyrosine hydroxylase (TH)-positive cells in the substantia nigra, and TH-positive fibers in the striatum. The results of this work elucidate the role of lactoferrin in protective and compensatory mechanisms and provide the basis for potential use of this protein in the treatment of human neurodegenerative diseases.We studied the effect of human lactoferrin (hLf) on degenerative changes in the nigrostriatal system and associated behavioral deficits in the animal model of Parkinson disease. Nigrostriatal dopaminergic injury was induced by single administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP; 40 mg/kg) to five-month-old C57Bl/6 mice. Behavioral disturbances were assessed in the open field and rotarod tests and by the stride length analysis. Structural deficits were assessed by the counts of tyrosine hydroxylase (TH)-immunoreactive neurons in the substantia nigra and optical density (OD) of TH-immunolabeled fibers in the striatum. Acute MPTP treatment induced long-term behavioral deficit and degenerative changes in the nigrostriatal system. Pretreatment with hLf prevented body weight loss and promoted recovery of motor functions and exploratory behavior. Importantly, OD of TH-positive fibers in the striatum of mice treated with hLf almost returned to normal, and the number of TH-positive cells in the substantia nigra significantly increased on day 28. These results indicate that hLf produces a neuroprotective effect and probably stimulates neuroregeneration under conditions of MPTP toxicity in our model. A relationship between behavioral deficits and nigrostriatal system disturbances at delayed terms after MPTP administration was found.

Highlights

  • Parkinson’s disease (PD), a progressive neurodegenerative disorder, is characterized by the degeneration of dopaminergic neurons in substantia nigra pars compacta (SNpc) and resultant depletion of dopamine (DA) in the striatum, leading to clinical symptoms of rigidity, tremor, and bradykinesia [1]

  • Dynamic assessment of locomotor and autonomic functions of mice treated with MPTP in the presence or absence of Lf showed that all types of extrapyramidal disorders were clearly manifested in ~2 min after the injection of

  • Dynamic assessment of locomotor and autonomic functions of mice treated with MPTP in the presence or absence of Lf sho6wofe1d7 that all types of extrapyramidal disorders were clearly manifested in ~2 min after the injection of neurotoxin

Read more

Summary

Introduction

Parkinson’s disease (PD), a progressive neurodegenerative disorder, is characterized by the degeneration of dopaminergic neurons in substantia nigra pars compacta (SNpc) and resultant depletion of dopamine (DA) in the striatum, leading to clinical symptoms of rigidity, tremor, and bradykinesia [1]. MPTP is a neurotoxin that upon systemic administration crosses the blood–brain barrier and selectively destroys dopaminergic neurons of the nigrostriatal system inducing a number of the symptoms observed in idiopathic PD [7,8]. This mouse model is limited by rapid development of toxicosis, while the idiopathic form of PD progresses slowly, and its inability to demonstrate persistent motor deficits. Its toxicity is determined by its active metabolite 1-methyl-4-phenylpyridium ion (MPP+) that is transported into neurons by the dopamine reuptake system and disturbs mitochondrial respiratory processes [9,10] This metabolite enhances lipid peroxidation, a process triggered by the overproduction of free radicals [11,12]

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call